All In Biotech

Drug Trial Radar · NCT05176639

A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)

A Safety, Tolerability, and Efficacy Study of Veligrotug, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor in Subjects With Thyroid Eye Disease

Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 113 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

113

Actual

Start

Nov 16, 2022

Primary completion

Jul 15, 2024

Study completion Mar 27, 2025

Sponsor

Lead sponsor
Viridian Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigational drug, veligrotug (VRDN-001), is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in participants with thyroid eye disease (TED). The primary objective of this clinical trial is to establish the safety, tolerability, and efficacy of veligrotug, and the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of veligrotug in active TED participants who received 10 milligrams (mg)/kilogram (kg).

Conditions

  • Thyroid Eye Disease

Interventions

  • VeligrotugDrug

    5 IV Infusions of veligrotug 10 mg/kg

  • PlaceboDrug

    5 IV Infusions of veligrotug matched placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proptosis Responder Rate (PRR) in the Study Eye As Measured by ExophthalmometerTime frame: Baseline to Week 15

Locations

53 sites in 7 countries. Site status is shown where the registry gives one.

  • University of Colorado - Department of Ophthalmology

    Aurora, California

  • The Private Office of Raymond Douglas

    Beverly Hills, California

  • USC Roski Eye Institute

    Los Angeles, California

  • MACRO Trials, Inc.

    Los Angeles, California

  • Amy Patel Jain, MD

    Newport Beach, California

  • Byers Eye Institute/Stanford University

    Palo Alto, California

  • Senta Clinic

    San Diego, California

  • University of California, San Francisco

    San Francisco, California

  • University of Colorado

    Aurora, Colorado

  • Sina Medical Center

    Homestead, Florida

  • Med-Care Research Inc.

    Miami, Florida

  • Edward Jenner Research Group Center LLC

    Plantation, Florida

  • Sarasota Retina Institute

    Sarasota, Florida

  • Vision Medical Research Inc.

    Orland Park, Illinois

  • University Health Diabetes, Endocrinology & Nephrology Center

    Kansas City, Kansas

  • KU Medical Center, University of Kansas

    Kansas City, Kansas

  • Massachusetts Eye and Ear

    Boston, Massachusetts

  • Ophthalmic Consultants of Boston

    Weymouth, Massachusetts

  • Fraser Eye Care Center

    Fraser, Michigan

  • Kahana Oculoplastic & Orbital Surgery

    Livonia, Michigan

  • University of Minnesota, Department of Ophthalmology and Visual Neurosciences

    Minneapolis, Minnesota

  • Advanced Research International, LLC

    Las Vegas, Nevada

  • Rutgers-New Jersey Medical School-Newark

    Newark, New Jersey

  • New York Eye Ear Infirmary of Mount Sinai

    New York, New York

  • Baylor College of Medicine (BCM)-Ophthalmology

    Houston, Texas

  • Neuro-Eye Clinical Trials

    Houston, Texas

  • Neuro-Ophthalmology of Texas PLLC

    Houston, Texas

  • University of Vermont Medical Center

    Burlington, Vermont

  • West Virgina University Eye Institute

    Morgantown, West Virginia

  • Sydney Eye Hospital

    Sydney, Australia

  • North Shore Eye Surgery

    Sydney, Australia

  • CHU d'Angers

    Angers, France

  • CH Nice

    Nice, France

  • Centre Hospitalier National D'ophtalmologie

    Paris, France

  • AP-HP- Hopital de la Pitie Salpetriere

    Paris, France

  • Universitatsmedizin Gottingen

    Göttingen, Germany

  • Johannes Gutenberg-University Medical Center

    Mainz, Germany

  • NZOZ E-Vita

    Bialystok, Poland

  • Specjakistyczny Osrodek Okulistyczny Oculomedica

    Bydgoszcz, Poland

  • Santa Familia PTG Lodz

    Lodz, Poland

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.